CGRP, VIP and PACAP plasmatic levels in migraine patients before and after anti-CGRP(R) monoclonal antibodies treatment
Cephalalgia · 2026-06 · 46 (6)
DOI: 10.1177/03331024261429802 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cephalalgia, online erschienen am 17.06.2026. Verfasst von Davide Chiasserini und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Surgery, Section of Physiology and Biochemistry, University of Perugia, Perugia, Italy. Hauptthemen laut MEDLINE: Pituitary Adenylate Cyclase-Activating Polypeptide, Vasoactive Intestinal Peptide, Calcitonin Gene-Related Peptide, Migraine Disorders. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: research grants provided by the Headache Center, University of Perugia, Ricerca Corrente 2025 - Italian Ministry of Health - to PC, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome..
Abstract (Originalsprache)
Aim
Calcitonin gene-related peptide (CGRP), vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating peptide (PACAP) play a crucial role in migraine pathophysiology. In recent years, anti-CGRP(R) monoclonal antibodies (mAbs) have emerged as the first targeted and highly effective therapy for migraine. This study aimed to assess any changes in plasma CGRP levels following prophylactic treatment with anti-CGRP(R) mAbs and to compare CGRP dynamics between anti-receptor (erenumab) and anti-ligand (galcanezumab, fremanezumab) therapies. Secondary objectives were: (i) to evaluate changes in VIP and PACAP plasma levels following treatment with anti-CGRP(R) mAbs and (ii) to investigate whether baseline or post-treatment plasma levels of CGRP, VIP and PACAP were associated with clinical response to anti-CGRP(R) monoclonal antibody therapy.
Methods
Between February 2022 and February 2023, we enrolled 56 migraine patients who initiated prophylaxis with either erenumab (26 patients), galcanezumab (16 patients) or fremanezumab (14 patients). Responders were defined as those achieving a ≥50% reduction in monthly migraine days after six months. Blood samples were collected at baseline and at each follow-up visit (baseline, T0; three months, T1; six months, T2; 12 months, T3). Plasma levels of CGRP, VIP and PACAP were measured using a validated radioimmunoassay and commercially available enzyme-linked immunosorbent assay kits.
Results
Overall, 80.3% (45 out of 56) of patients responded to anti-CGRP(R) mAbs. No correlation was found between baseline CGRP, VIP and PACAP plasma levels and clinical response to anti-CGRP(R) mAbs therapy. Regarding CGRP trend, significant differences were found between patients treated with the anti-receptor monoclonal antibody (erenumab) and those receiving anti-ligand therapies. In patients treated with erenumab, CGRP levels did not show a significant change over the treatment period (T1–T3), whereas, in the galcanezumab group, CGRP levels significantly decreased as early as T1 ( p < 0.01). CGRP longitudinal assessment of the fremanezumab group were excluded due to assay interference with the drug. VIP and PACAP plasma levels remained stable over time for all treatments, with no significant differences between responders and non-responders.
Conclusions
Galcanezumab reduced CGRP plasmatic levels already after three months, whereas erenumab did not affect significantly CGRP plasmatic levels. VIP and PACAP levels were not influenced by the therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine and Surgery, Section of Physiology and Biochemistry, University of Perugia, Perugia, Italy.
- Headache Center, Department of Neurology, Neurocenter of Southern Switzerland, EOCLugano, Switzerland.
- Department of Medicine and Surgery, Section of Neurology, University of Perugia, Perugia, Italy.
- Center for Memory Disturbances, Lab of Clinical Neurochemistry, Section of Neurology, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
- Department of Healthcare Surveillance and Bioethics, Section of Pharmacology, Catholic University Medical School, Fondazione Policlinico Universitario Agostino Gemelli-IRCCS, Rome, Italy.
- Department of Medicine and Surgery, Section of Internal Medicine, University of Perugia, Perugia, Italy.
ORCID-Profile: Davide Chiasserini, Alessia Bellotti, Alfredo Megaro, Giuseppe Tringali, Ilenia Corbelli, Elena Cresta, Valeria Teti, Daniela Fruttini, Paolo Calabresi, Pierluigi Navarra, Lucilla Parnetti, Paola Sarchielli
Förderung
- research grants provided by the Headache Center, University of Perugia
- Ricerca Corrente 2025 - Italian Ministry of Health - to PC, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome.
Zitieren
APA
Chiasserini, D., Bellotti, A., Megaro, A., Tringali, G., Corbelli, I., Cresta, E., Teti, V., Fruttini, D., Calabresi, P., Navarra, P., Parnetti, L., & Sarchielli, P. (2026). CGRP, VIP and PACAP plasmatic levels in migraine patients before and after anti-CGRP(R) monoclonal antibodies treatment. Cephalalgia, 46(6). https://doi.org/10.1177/03331024261429802
Vancouver
Chiasserini D, Bellotti A, Megaro A, Tringali G, Corbelli I, Cresta E, et al. CGRP, VIP and PACAP plasmatic levels in migraine patients before and after anti-CGRP(R) monoclonal antibodies treatment. Cephalalgia. 2026;46(6). doi:10.1177/03331024261429802
BibTeX
@article{Chiasserini2026,
author = {Chiasserini, Davide and Bellotti, Alessia and Megaro, Alfredo and Tringali, Giuseppe and Corbelli, Ilenia and Cresta, Elena and Teti, Valeria and Fruttini, Daniela and Calabresi, Paolo and Navarra, Pierluigi and Parnetti, Lucilla and Sarchielli, Paola},
title = {CGRP, VIP and PACAP plasmatic levels in migraine patients before and after anti-CGRP(R) monoclonal antibodies treatment},
journal = {Cephalalgia},
year = {2026},
volume = {46},
number = {6},
doi = {10.1177/03331024261429802}
}
EUVIMED